Published in Int J Mol Sci on November 05, 2014
The Small C-terminal Domain Phosphatase 1 Inhibits Cancer Cell Migration and Invasion by Dephosphorylating Ser(P)68-Twist1 to Accelerate Twist1 Protein Degradation. J Biol Chem (2016) 0.78
Super natural killer cells that target metastases in the tumor draining lymph nodes. Biomaterials (2015) 0.78
Nanoformulation of Geranylgeranyltransferase-I Inhibitors for Cancer Therapy: Liposomal Encapsulation and pH-Dependent Delivery to Cancer Cells. PLoS One (2015) 0.75
CD169 identifies an activated CD8(+) T cell subset in regional lymph nodes that predicts favorable prognosis in colorectal cancer patients. Oncoimmunology (2016) 0.75
Selective interaction of PEGylated polyglutamic acid nanocapsules with cancer cells in a 3D model of a metastatic lymph node. J Nanobiotechnology (2016) 0.75
Involvement of chemokine receptors in breast cancer metastasis. Nature (2001) 26.07
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol (2010) 24.08
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Microenvironmental regulation of metastasis. Nat Rev Cancer (2008) 15.76
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
Tumor metastasis: mechanistic insights and clinical challenges. Nat Med (2006) 11.06
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
The immunobiology of cancer immunosurveillance and immunoediting. Immunity (2004) 9.39
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med (1988) 8.90
Microenvironmental regulation of tumor progression and metastasis. Nat Med (2013) 8.37
Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med (2001) 7.78
Human natural killer cells. Blood (2008) 7.37
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med (1987) 7.33
Homing and cellular traffic in lymph nodes. Nat Rev Immunol (2003) 7.23
Progress in human tumour immunology and immunotherapy. Nature (2001) 6.97
The central role of CD4(+) T cells in the antitumor immune response. J Exp Med (1998) 6.02
Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol (2004) 5.80
Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37
Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol (2005) 5.09
Immune surveillance of tumors. J Clin Invest (2007) 5.04
The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. Immunity (2005) 4.72
Treatment of metastatic melanoma: an overview. Oncology (Williston Park) (2009) 4.58
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest (2007) 4.44
Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest (2004) 4.27
Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A (2004) 4.12
Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. Trends Immunol (2003) 3.91
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med (1997) 3.89
Illuminating the metastatic process. Nat Rev Cancer (2007) 3.80
Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res (2011) 3.73
Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev (2009) 3.56
Innate immunity: an overview. Mol Immunol (2004) 3.50
Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res (2000) 3.47
Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst (2002) 3.44
Microlymphatics and lymph flow. Physiol Rev (1990) 3.33
4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med (1997) 3.31
Cancer immunotherapy by dendritic cells. Immunity (2008) 3.09
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol (2001) 3.05
Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med (2000) 3.04
Cancer immunoediting from immune surveillance to immune escape. Immunology (2007) 3.03
Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol (2004) 3.00
Intercellular adhesion molecule-1-dependent stable interactions between T cells and dendritic cells determine CD8+ T cell memory. Immunity (2008) 2.98
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol (2007) 2.92
The physiology of the lymphatic system. Adv Drug Deliv Rev (2001) 2.72
Primary antitumor immune response mediated by CD4+ T cells. Immunity (2005) 2.72
NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol (2001) 2.71
The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol (2004) 2.64
Development of TLR9 agonists for cancer therapy. J Clin Invest (2007) 2.64
CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med (1999) 2.61
Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A (1997) 2.53
Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest (2011) 2.44
NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol (2013) 2.39
Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res (2006) 2.37
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med (2001) 2.37
Natural killer cell behavior in lymph nodes revealed by static and real-time imaging. J Exp Med (2006) 2.30
Microenvironmental regulation of cancer development. Curr Opin Genet Dev (2008) 2.25
Multiplex B cell characterization in blood, lymph nodes, and tumors from patients with malignancies. J Immunol (2013) 2.20
Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow. Blood (2011) 2.17
Insights into the mechanisms of lymph node metastasis. Cancer (2003) 2.15
Normal structure, function, and histology of lymph nodes. Toxicol Pathol (2006) 2.13
Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med (2004) 2.13
Detection of cancer micrometastases in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res (1995) 2.07
Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med (1998) 2.03
Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol (2003) 2.00
Natural killer cells and cancer. Adv Cancer Res (2003) 1.99
Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell (2012) 1.95
Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat Rev Cancer (2014) 1.95
Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene (2008) 1.94
CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res (2007) 1.94
Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol (1999) 1.89
Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother (2003) 1.88
Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res (1995) 1.87
Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol (2006) 1.81
Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules. Nature (2011) 1.80
The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev (1996) 1.78
Molecular control of lymphatic metastasis. Ann N Y Acad Sci (2008) 1.72
Tumor and lymph node lymphangiogenesis--impact on cancer metastasis. J Leukoc Biol (2006) 1.72
Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol (2013) 1.70
Natural killer cells in human health and disease. Clin Immunol (2005) 1.68
CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer (2007) 1.64
Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res (2014) 1.63
Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev (2001) 1.62
The tumor-draining lymph node as an immune-privileged site. Immunol Rev (2006) 1.57
NK cells and cancer. J Immunol (2007) 1.56
Pathways targeting tumor lymphangiogenesis. Clin Cancer Res (2006) 1.56
Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst (2002) 1.56
Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest (2006) 1.56
Liposomes: technologies and analytical applications. Annu Rev Anal Chem (Palo Alto Calif) (2008) 1.55
Tumor metastasis and the lymphatic vasculature. Int J Cancer (2009) 1.51
Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells. J Exp Med (2003) 1.49
Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: implications for tumor biology and treatment. Mod Pathol (2001) 1.48
Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology (2009) 1.48
Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med (2009) 1.47
HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today (1999) 1.47
Dendritic cells in the cancer microenvironment. J Cancer (2012) 1.40
Natural T cell immunity against cancer. Clin Cancer Res (2003) 1.36
How melanoma cells evade trail-induced apoptosis. Nat Rev Cancer (2001) 1.32
TRAIL-coated leukocytes that kill cancer cells in the circulation. Proc Natl Acad Sci U S A (2014) 1.31
Prognostic significance of level and number of lymph node metastases in patients with gastric cancer. Ann Surg Oncol (2007) 1.31